

Policy: MP053

Section: Medical Benefit Policy

Subject: Cochlear Implant

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Cochlear Implant

II. Purpose/Objective:

To provide a policy of coverage regarding Cochlear Implant

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an

illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

Compressed array: electrodes placed along a shorter linear implant of approx. 12-13 mm for use in cases of cochlear ossification or malformation which makes complete insertion of a standard array impossible.

Limited benefit from amplification is defined as: Test scores of $\leq 30\%$ correct in the best-aided listening condition, in tests of open set sentence recognition.

Profound hearing loss – hearing threshold of 90 decibels or greater

Severe hearing loss – bilateral hearing threshold of 70-90 decibels (db)

Split array: electrodes are placed along two separate linear implants ranging from approx. 4-9 mm for use in cases of profound cochlear ossification.

Standard array: electrodes are placed along a linear implant of approx. 26 mm. Unless otherwise noted, cochlear implants use a standard array.

DESCRIPTION:

The cochlear implant is a single or multiple channel device intended to restore a level of auditory sensation to individuals with severe to profound sensorineural hearing loss by means of electrical stimulation of the auditory nerve. The components common to most models include: a microphone, an external signal processor, an internal receiver, and an electrode array implanted in the cochlea. Sounds picked up by the microphone are carried to the external signal processor that transforms sound into electrical signals. These signals are transmitted to the internal receiver implanted in the temporal bone, which activates the wire implanted in the cochlea.

INDICATIONS:

Single or multiple channel unilateral or bilateral cochlear implants will be considered medically necessary when **ALL** of the following criteria are met:

- The member must be at least 9 months of age with bilateral, moderate-to-profound sensorineural deafness (70 decibels or greater).
- The member must be unable to benefit from a hearing aid (open sentence recognition score of 40% or less under optimal aided circumstance)
- The device must be an FDA approved cochlear implant.

In addition, certain members in the Medicare Business Segment may be eligible for cochlear implants as listed below:

- Members with hearing test scores of greater than 40% to less than or equal to 60% when the device and services are provided as part of a prospective, controlled comparative trial approved by CMS

Unilateral or Asymmetric Sensorineural Hearing Loss

Cochlear implants for unilateral sensorineural hearing loss are considered medically necessary when all of the following medical criteria are met:

- The member is 5 years of age or older; and
- The member has realized no or only marginal speech perception benefit from a one-month trial of hearing aid (CROS or other relevant nonimplantable device) in ear to be implanted; and
 - Single-sided deafness (SSD) with profound sensorineural hearing loss in in one ear and normal or mild to moderate sensorineural hearing loss in the other ear with a difference of at least 15 dB in pure tone averages (PTA) between ears.

Hybrid cochlear implant will be considered medically necessary when **ALL** of the following criteria are met:

- The member is 18 years of age and has a diagnosis of bilateral severe-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity; and
- The member obtains limited benefit from appropriately fit bilateral hearing aids; and
- The following hearing thresholds are met in the ear selected for implantation:
 - Low-frequency (125 -500hz) hearing thresholds no poorer than 60 dB hearing level
 - Severe to profound mid- to high-frequency (2000 - 4000 Hz) hearing loss ≥ 75 dB hearing level
 - Aided consonant-nucleus-consonant word recognition score from 10% to 60% in the preoperative aided condition
- The following hearing thresholds are met in the contralateral ear:

- Moderately severe to profound mid-to-high frequency (2000 – 4000Hz) hearing loss greater than or equal to 60 dB hearing level; and
- Aided consonant-nucleus-consonant word recognition score equal to or better than that of the ear selected for implantation but not more than 80 percent correct
- There are no contraindications including but not limited to **ANY** of the following:
 - Chronic or active infection of the external or middle ear or mastoid cavity in the ear selected for implantation; or
 - Tympanic membrane perforation; or
 - Evidence of agenesis of the cochlea in the ear selected for implantation; or
 - Etiology of deafness is due to lesions of the brainstem, or
 - Etiology of deafness is due to lesions of the eighth cranial nerve or central auditory pathway

***NOTE: Age-appropriate vaccination against pneumococcal disease, H influenza type B, and meningococcal disease is required prior to implantation.**

The Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommends vaccination against pneumococcal disease for persons at increased risk for pneumococcal meningitis. Because data suggest a higher risk for pneumococcal meningitis in cochlear implant recipients, the CDC recommends that these individuals should receive the age-appropriate vaccination using the 13 7-valent pneumococcal conjugate (Pneumovax®) or 23-valent pneumococcal polysaccharide (Pneumovax® and Pne-Immune®) vaccine according to ACIP schedules for persons at high risk.

The FDA offered an additional recommendation to decrease the risk of meningitis in cochlear implant recipients. The document is available for review at: <http://www.fda.gov/cdrh/safety/101007-cochlear.html>

EXCLUSIONS:

Use of cochlear implant is contraindicated in the following:

- Deafness due to lesions of the acoustic nerve or central auditory pathway
- Otitis media or other unresolved ear problems
- Radiographic evidence of absent cochlear development

The Plan does not cover the replacement of external components with upgraded components when done solely to improve appearance or to treat psychological symptomatology or complaints because it is considered **not medically necessary**.

Frequency modulated (FM) systems are used as an extension or accessory of cochlear implants and are not integral to the function of the cochlear implant itself. These devices are considered **not medically necessary**.

LIMITATIONS:

Repair and/or replacement of processor will be covered under the applicable benefit document if implant met FDA guidelines, and to the extent not covered by the warranty.

Replacement batteries and cables are not covered for most contracts.

Replacement batteries and cables are covered with prior authorization only for GHP Family line of business.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Cochlear Implant

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or

the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements

- 69930 Cochlear device implantation, with or without mastoidectomy
- 92601 Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming
- 92602 subsequent programming
- 92603 Diagnostic analysis of cochlear implant, patient age 7 years or older; with programming
- 92604 subsequent programming
- L8614 Cochlear device includes all internal and external components
- L8615 Headset/headpiece for Use with cochlear implant device, replacement
- L8616 Microphone for Use with cochlear implant device, replacement
- L8617 Transmitting coil for Use with cochlear implant device, replacement
- L8618 Transmitter cable for Use with cochlear implant device, replacement
- L8619 Cochlear implant external speech processor, replacement
- L8621 Zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each
- L8622 Alkaline battery for Use with cochlear implant device, any size, replacement, each
- L8623 Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each
- L8624 Lithium ion battery for use with cochlear implant device speech processor, ear level, replacement, each
- L8625 External recharging system for battery for use with cochlear implant or auditory osseointegrated device, replacement only, each
- L8627 Cochlear implant, external speech processor component, replacement
- L8628 Cochlear implant, external controller component, replacement
- L8629 Transmitting coil and cable integrated, for use with cochlear implant device
- L8694 Auditory osseointegrated device, transducer/actuator, replacement only, each

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supersede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

- EI-Hakim H, Levasseur J, Papsin BC, Panesar J, Mount RJ, Stevens D, Harrison RV, "Assessment of Vocabulary Development in Children After Cochlear Implantation", *Archives of Otolaryngology – Head & Neck Surgery*, 127(9):1053-1059, Sept 2001.
- Luntz M, Teszler CB, Shpak T, Feiglin H, Farah-Sima'an A, "Cochlear Implantation in Healthy and Otitis Prone Children: A Prospective Study", *Laryngoscope*, 111(9):1614-1618, Sept 2001.
- Black FO, Lilly DJ, Fowler LP, Stypulkowski PH, "Surgical Evaluation of candidates for Cochlear Implants", *Annals of Otolaryngology, Rhinology and Laryngology*, 96(1 Pt 2 Suppl 128):96-99, Jan – Feb 1987.
- Valimaa TT, Sorri MJ, Lopponen HJ, "Speech perception and Functional Benefit After Multichannel Cochlear Implantation", *Scandinavian Audiology*, Supplement 52:45-47, 2001.
- Zwolaan T, Kileny PR, Smith S, Mills D, Koch D, Osterberger MJ, "Adult Cochlear Implant Patient Performance with Evolving Electrode Technology", *Otology & Neurotology* 22(6):844-849, Nov 2001.
- Cohen NL, Waltzman SB, Fisher SG, The Department of Veterans Affairs Cochlear Implant Study Group, "A Prospective, Randomized Study of Cochlear Implants", *The New England Journal of Medicine*, 328(4):233-237, 28 Jan 1993.
- NIH Consensus Conference, "Cochlear Implants in Adults and Children", *JAMA* 274(24):1955-1961, 27 Dec 1995.
- Centers for Disease Control, Morbidity and Mortality Weekly Report, "Pneumococcal Vaccination for Cochlear Implant Candidates and recipients: Updated Recommendations of the Advisory Committee on Immunization Practices". 52(31):739-740. Aug. 8, 2003.
- Reefhuis J, Honein MA, Whitney CG, et. al., "Risk of Bacterial Meningitis in Children with Cochlear Implants", *New England Journal of Medicine*, 349(5):435-445. July 31, 2003.
- Centers for Medicare and Medicaid Services, Decision Memo, Cochlear Implant CAG-00107N April 5, 2005.

Winifred S. Hayes, INC. Hayes Directory – Cochlear Implantation. Hayes Inc: Lansdale Pa. September 12, 2005. Updated September 2006.

Biernath KR, Reefhuis J, Whitney CG, Mann EA, Costa P, Eichwald J, Boyle C. Bacterial meningitis among children with cochlear implants beyond 24 months after implantation. February 2006;117(2):284-289.

American Academy of Otolaryngology-Head and Neck Surgery. AAO-HNS Position Statement - Cochlear Implants. 2014. updated 2020. <http://www.entnet.org/content/position-statement-cochlear-implants>.

Raman G, Lee J, Chung M, et al. Effectiveness of cochlear implants in adults with sensorineural hearing loss. Technology Assessment Report. Prepared by the Tufts Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ). June 17, 2011. Available at URL address: <https://www.cms.gov/determinationprocess/downloads/id80TA.pdf>

National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 166. Cochlear implants for children and adults with severe to profound deafness. Review Date: February 2011. Accessed at: <http://www.nice.org.uk/nicemedia/pdf/TA166Guidancev2.pdf>

Bond M, Mealing S, Anderson R, Elston J, Weiner G, Taylor RS, Hoyle M, Liu Z, Price A, Stein K. The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model. Health Technol Assess. 2009 Sep;13(44):1-330

Gaylor, JM., Raman, G., Chung, M., et al. Cochlear implantation in adults: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2013; 139(3): 265-72.

Vincenti, V., Bacciu, A., Guida, M., Marra, F., Bertoldi, B., Bacciu, S., Pasanisi, E. Pediatric cochlear implantation: an update. Ital J Pediatr. 2014; 40:72.

Centers for Disease Control and Prevention (CDC). Use of vaccines to prevent meningitis in persons with cochlear implants. Fact Sheet. Atlanta, GA: CDC; updated June 19, 2015

Farinetti A, Ben Gharbia D, Mancini J, et al. Cochlear implant complications in 403 patients: Comparative study of adults and children and review of the literature. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(3):177-182

Peters JP, Ramakers GG, Smit AL, Grolman W. Cochlear implantation in children with unilateral hearing loss: A systematic review. Laryngoscope. 2016;126(3):713-721.

El-Anwar MW, El-Aassar AS, Foad YA. Non-mastoidectomy cochlear implant approaches: A literature review. Int Arch Otorhinolaryngol. 2016;20(2):180-184.

Lenarz, T, James, C, Cuda, D, et al. European multi-centre study of the Nucleus Hybrid L24 cochlear implant. International journal of audiology. 2013 Dec;52(12):838-48.

Friedmann, DR, Peng, R, Fang, Y, McMenomey, SO, Roland, JT, Waltzman, SB. Effects of loss of residual hearing on speech performance with the CI422 and the Hybrid-L electrode. Cochlear Implants Int. 2015 Sep;16(5):277-84.

Sladen, DP, Carlson, ML, Dowling, BP, et al. Early outcomes after cochlear implantation for adults and children with unilateral hearing loss. The Laryngoscope. 2017 Jul;127(7):1683-8.

Sladen, DP, Frisch, CD, Carlson, ML, Driscoll, CL, Torres, JH, Zeitler, DM. Cochlear implantation for single-sided deafness: A multicenter study. The Laryngoscope. 2017 Jan;127(1):223-8.

Roland JT, Jr., Gantz BJ, Waltzman SB, et al. United States multicenter clinical trial of the cochlear nucleus hybrid implant system. Laryngoscope. Jan 2016;126(1):175-181.

Vesseur A, Free R, Snels C, et al. Hearing restoration in cochlear nerve deficiency: The choice between cochlear implant or auditory brainstem implant, a meta-analysis. Otol Neurotol. 2018;39(4):428-437.

Kraaijenga VJC, Derksen TC, Stegeman I, Smit AL. The effect of side of implantation on unilateral cochlear implant performance in patients with prelingual and postlingual sensorineural hearing loss: A systematic review. Clin Otolaryngol. 2018b;43(2):440-449.

U.S. Food and Drug Administration. Nucleus 24 Cochlear Implant System. Approval amendment. March 17, 2020

Hayes Inc. Hayes Evidence Analysis Research Brief. Cochlear implantation for adults with single-sided deafness and tinnitus. October 2020.

Hwa TP, Sturm JJ, Losenegger T, et al. Impact of underlying diagnosis on speech and quality of life outcomes after cochlear implantation for single-sided deafness. *Otol Neurotol*. 2020 Apr;41(4):e432-e440.

Nicolas S, Gallois Y, Calmels MN, et al. Quality of life of children treated for unilateral hearing loss: a systematic review and meta-analysis. *Arch Dis Child*. 2021 Feb 26

Thompson NJ, Dillon MT, Buss E, et al. Subjective benefits of bimodal listening in cochlear implant recipients with asymmetric hearing loss. *Otolaryngol Head Neck Surg*. 2020 Jun;162(6):933-941.

Poncet-Wallet C, Mamelle E, Godey B, et al. Prospective multicentric follow-up study of cochlear implantation in adults with single-sided deafness: tinnitus and audiological outcomes. *Otol Neurotol*. 2020 Apr;41(4):458-46

Marx M, Mosnier I, Venail F, et al. Cochlear implantation and other treatments in single-sided deafness and asymmetric hearing loss: results of a National Multicenter Study including a randomized controlled trial. *Audiol Neurootol*. 2021; 26(6): 414-424.

Benchetrit L, Ronner EA, Anne S, et al. Cochlear implantation in children with single-sided deafness: A systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg*. 2021; 147(1): 58-69

Peters JPM, van Heteren JAA, Wendrich AW, et al. Short-term outcomes of cochlear implantation for single-sided deafness compared to bone conduction devices and contralateral routing of sound hearing aids-Results of a Randomized controlled trial (CINGLE-trial). *PLoS One*. 2021; 16(10): e0257447.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 6/95

Revised: 11/95, 3/97, 8/98, 1/02, 1/03 Coding; 8/03 add vaccine requirement and limitation; 9/04 definitions, criteria clarification; 7/05 (CMS expanded criteria);8/06;8/07 (age Requirement); 8/08 (FDA recommendation); 12/10 (coding, removal of attachment), 12/11(added unilateral/bilateral to indications), 4/13 (clarification for battery coverage); 7/16, 8/18 (Revised Indications); 8/19 (add FM system exclusion); 8/20 (lower age limitation to 9 mo); 8/21(added unilateral hearing loss indication)

Reviewed: 11/09 (format), 12/12, 12/13, 12/14, 8/15, 7/17, 8/22

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.